Innovative direct purchase agreement sees adalimumab biosimilar prices slashed

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Innovative direct purchase agreement sees adalimumab biosimilar prices slashed

Biosimilars/General | Posted 15/10/2024 0 Post your comment

On 1 October 2024, Blue Shield of California in the US announced that it will pay far less for an adalimumab biosimilar. The transparent net price paid by the health plan provider will be US$525 per monthly dose, compared to the market-reported net price of reference product Humira at US$2,100.

This comes as a result of an innovative direct purchase agreement with Evio Pharmacy Solutions and drug manufacturer Fresenius Kabi. This eliminates the markups often found in a traditional pharmacy benefit manager model. Now, Blue Shield’s new Pharmacy Care Reimagined model allows the nonprofit health plan to provide its members with better access to biosimilar medications.

When it comes to biosimilars, which are supposed to facilitate access to lower-priced treatment options, complex pharmacy value chains can create barriers and misaligned incentives for uptake. However, now, Evio’s alternative payment model eliminates traditional rebate strategies and transparently aligns incentives between health plans and manufacturers to unlock the value of biosimilars.

From 1 January 2025, most Blue Shield commercial members using Fresenius Kabi’s adalimumab biosimilar will pay US$0 out of pocket. Overall, this will bring drug spend down and it is expected to increase medication. This will be a benefit in terms of care cost and member health outcomes.

‘This agreement will have transformational economic impact for Evio customer health plans and their members,’ said Matt Seibt, Head of Pharmaceutical Partnerships at Evio, who led the strategy and negotiations. ‘Evio is perfectly positioned to play an integral role in the adoption of biosimilars, and given the coming biosimilar wave, we are actively working on similar arrangements for a number of biosimilars in the pipeline.’

Adalimumab is a human monoclonal antibody treats autoimmune diseases including rheumatoid arthritis, juvenile idiopathic and psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis [1].

Despite the availability of several adalimumab biosimilars in the US, the originator product, Humira, retains a large portion of patients [2]. This new agreement hopes to change the landscape for this treatment option.

LATIN AMERICAN FORUM
The objective of GaBI’s Latin American Forum is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Un innovador acuerdo de compra directa permite reducir drásticamente los precios de los biosimilares de adalimumab

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO
El objetivo del Foro Latinoamericano de GaBI es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Un innovador acuerdo de compra directa permite reducir drásticamente los precios de los biosimilares de adalimumab

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of adalimumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Oct 15]. Available from: www.gabionline.net/biosimilars/general/biosimilars-of-adalimumab
2. GaBI Online - Generics and Biosimilars Initiative. Humira's resilience in the face of biosimilar competition [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Oct 15]. Available from: www.gabionline.net/biosimilars/general/humira-s-resilience-in-the-face-of-biosimilar-competition

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.